Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.65 |
| ▸ | F10 | P00742 | 2/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | ALPL | P05186 | 1/20 | 0.56 |
| ▸ | ALPI | P09923 | 1/20 | 0.56 |
| ▸ | ALPG | P10696 | 1/20 | 0.56 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.49 |
| ▸ | AMY1A | P0DUB6 | 4/20 | 0.49 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | MPO | P05164 | 1/20 | 0.46 |
| ▸ | METAP2 | P50579 | 2/20 | 0.45 |
| ▸ | METAP1 | P53582 | 2/20 | 0.45 |
| ▸ | CBFB | Q13951 | 1/20 | 0.45 |
| ▸ | RAD52 | P43351 | 1/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.45 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31345724 | 1.00 | IDO1 (0.66) | IDO1TDP1F10NPSR1ALPL | |
| SCHEMBL5774011 | 0.86 | TDP1 (0.51) | IDO1TDP1F10NPSR1ALPL | |
| SCHEMBL38661663 | 0.82 | IDO1 (0.76) | IDO1TDP1F10ALPLALPI | |
| SCHEMBL4070449 | 0.82 | IDO1 (0.66) | IDO1TDP1F10ALPLALPI | |
| SCHEMBL10271748 | 0.82 | IDO1 (0.66) | IDO1F10ALPLALPIALPG | |
| SCHEMBL38661086 | 0.80 | IDO1 (0.59) | IDO1F10NPSR1ALPLALPI | |
| SCHEMBL19383787 | 0.79 | IDO1 (1.00) | IDO1TDP1F10ALPLALPI | |
| SCHEMBL12582726 | 0.79 | TDP1 (0.65) | TDP1F10NPSR1RAD52PIK3CD | |
| SCHEMBL520978 | 0.79 | RAD52 (0.69) | TDP1NPSR1RAD52POLBKMT2A | |
| SCHEMBL12636194 | 0.79 | TDP1 (1.00) | IDO1TDP1F10NPSR1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9884832-B2 | Inhibitors targeting drug-resistant influenza A | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2018-02-06 | — | — | US | disclosed |
| US-20150191439-A1 | INHIBITORS TARGETING DRUG-RESISTANT INFLUENZA A | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-07-09 | — | — | US | disclosed |
| WO-2013086131-A1 | INHIBITORS TARGETING DRUG-RESISTANT INFLUENZA A | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2013-06-13 | — | — | WO | disclosed |
| EP-1311268-A4 | IMIDAZOPYRIDINE AND IMIDAZOPYRIMIDINE ANTIVIRAL AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2004-06-30 | — | — | EP | disclosed |
| CN-1436079-A | Imidazopyridine and imidazopyrimidine antiviral agent | BRISTOL MYERS SQUIBB CO (US) | 2003-08-13 | — | — | CN | disclosed |
| EP-1311268-A1 | IMIDAZOPYRIDINE AND IMIDAZOPYRIMIDINE ANTIVIRAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-05-21 | — | — | EP | disclosed |
| US-6489338-B2 | TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS INFECTION. | BRISTOL-MYERS SQUIBB COMPANY | 2002-12-03 | — | — | US | disclosed |
| US-20020016309-A1 | Imidazopyridine and imidazopyrimidine antiviral agents | BRISTOL-MEYERS SQUIBB COMPANY | 2002-02-07 | — | — | US | disclosed |
| WO-2001095910-A1 | IMIDAZOPYRIDINE AND IMIDAZOPYRIMIDINE ANTIVIRAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150191439-A1 | INHIBITORS TARGETING DRUG-RESISTANT INFLUENZA A | HAVCR2, HDLBP, HSP90B1 | IDO1 342/4885TDP1 4463/4885F10 2688/4885 |
| US-20020016309-A1 | Imidazopyridine and imidazopyrimidine antiviral agents | MAVS, ZC3HAV1, EIF2AK2 | IDO1 235/4885TDP1 1773/4885F10 4038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.